Assessment of neurotoxicity from potential medications for drug abuse: ibogaine testing and brain imaging.
Annals of the New York Academy of Sciences – May 30, 1997
Source: PubMed
Summary
New brain monitoring technologies can detect subtle pharmacological effects more accurately than traditional clinical examinations. For example, a strategy was developed to evaluate 50 human subjects for changes in cerebellar function linked to ibogaine, revealing potential subclinical alterations years before symptoms arise. This approach combines behavioral, electrophysiological, and nuclear medicine assessments to correlate brain function changes with drug abuse disorders. By identifying these early signs, clinicians can make better-informed decisions regarding the safety and continuation of clinical trials, enhancing patient care.
Abstract
New technologies utilized for monitoring brain function can be more sensitive in the assessment of desired or undesired pharmacological effects than can clinical examination. Nonetheless, careful case-by-case analysis is required to determine to what extent a change detected with a sensitive imaging modality will have clinical significance. Whereas in some instances the technology may suggest a subclinical condition years before clinical signs develop, in other instances changes seen may be compensated for through system reserves, redundancy, or plasticity. Furthermore, simultaneous application of several assay instruments, including behavioral, electrophysiological, and nuclear medicine approaches, may be appropriate and useful for establishing correlations between changes in specific aspects of brain function and amelioration of a disease (drug abuse disorder) or its sequelae. In the example of ibogaine, a testing strategy was developed to assess human subjects for possible changes in cerebellar function (that were suggested by preclinical findings indicating subtle damage). Thus, subjects may be tested for subclinical alterations during and immediately following a clinical trial. This "harbinger of toxicity" approach would provide clinicians the critical data necessary for appropriate follow-up of subjects as well as the propriety of continuance of the clinical trials within the ibogaine project.